canSAR has grown significantly as the leading public oncology drug discovery resource. It now contains >10 billion experimental measurements across multiple disciplines, incorporating patient molecular profiling, medicinal chemistry, structural and systems biology and clinical studies. These data benefit from extensive curation, standardisation and insights. The current canSAR release is the most comprehensive, up-to-date and unique provider of target ‘druggability’ and ligandability assessment.
